We at TIEFEENBACHER PHARMACEUTICALS strongly believe that our high-quality medicines should be available for all patients around the world – irrespective of their origin or nationality. That´s why Tiefenbacher Pharmaceuticals is happy to share that we have successfully expanded the launch of the generic version of Rivaroxaban to Central America, the Caribbean and Kazakhstan.
Rivaroxaban is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. The tablets are marketed in the strengths 10 mg, 15 mg, and 20 mg by our cooperation partner, one of the biggest generic pharmaceutical companies in the world. The product has been developed in TIEFENBACHER GROUP´s own laboratories in Hyderabad, India, and has already been launched in certain patent-free European markets before. A launch in further international countries like Thailand, Albania, Serbia, Peru, Chile, and North Macedonia will follow soon. Overall, our country scope covers about 80 countries around the world. With this global market entry, we enable millions of patients worldwide access to a life- improving, high-quality treatment – also in emerging countries where GMP-compliance is not always a standard yet.
We will keep you updated about launches of this and other products in further international markets.
For further information about our pharmaceuticals or medical devices please contact TIEFENBACHER PHARMACEUTICALS: info@aet.eu
TIEFENBACHER PHARMACEUTICALS is a part of TIEFENBACHER GROUP – pioneering healthcare since 1963. Please visit us on: www.aet.eu and www.tiefenbachergroup.com
